HYPERTENSION, PULMONARY
Clinical trials for HYPERTENSION, PULMONARY explained in plain language.
Never miss a new study
Get alerted when new HYPERTENSION, PULMONARY trials appear
Sign up with your email to follow new studies for HYPERTENSION, PULMONARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with rare lung disease as drug trial advances
Disease control OngoingThis study tested the safety and correct dose of the drug riociguat in 24 children aged 6 to 18 with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard for the heart to pump blood. The children took different doses over several weeks, and researche…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 11:19 UTC
-
Hope for kids with rare lung disease: new drug combo aims to slow progression
Disease control OngoingThis study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH), a serious lung condition. About 138 children will receive either selexipag or a placebo, and researchers will track how…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated May 26, 2026 11:14 UTC
-
New hope for PAH patients: Long-Term drug safety trial opens
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called ralinepag for people with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. About 1,000 adults who were in earlier ralinepag studies can join. The goal is to see if the drug is …
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC